Who are Hu38Sb19's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SARCLISA, Darzalex, ISATUXIMAB, Darzalex Faspro.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/isatuximab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Hu38Sb19 — Competitive Intelligence Brief

Hu38Sb19 (isatuximab) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CD38-directed Cytolytic Antibody. Area: Oncology.

discontinued CD38-directed Cytolytic Antibody Lymphocyte differentiation antigen CD38 Oncology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Hu38Sb19 (isatuximab) — Sanofi. Isatuximab works by binding to the CD38 protein on cancer cells, triggering a response that leads to their destruction.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Hu38Sb19 TARGET	isatuximab	Sanofi	discontinued	CD38-directed Cytolytic Antibody	Lymphocyte differentiation antigen CD38	2020-01-01
SARCLISA	ISATUXIMAB-IRFC	SANOFI AVENTIS US	marketed	CD38-directed Cytolytic Antibody [EPC]	Lymphocyte differentiation antigen CD38
Darzalex	Darzalex	Shanghai Henlius Biotech	marketed		Lymphocyte differentiation antigen CD38
ISATUXIMAB	ISATUXIMAB		marketed	CD38-directed Cytolytic Antibody [EPC]		2020-01-01
Darzalex Faspro	daratumumab-and-hyaluronidase-fihj	Pfizer	marketed	CD38-directed Cytolytic Antibody [EPC]	CD38	2020-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CD38-directed Cytolytic Antibody class)

Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hu38Sb19 — Competitive Intelligence Brief. https://druglandscape.com/ci/isatuximab. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab